JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
Category: dates
Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
L. Walther et al.AACR 2023Download the poster herePoster Presentation
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
Appointment of Carol Stuckley as New Independent Director 15
Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
Availability of Preparatory documents for the combined general meeting of May 5, 2023 15
Availability of Transgene’s 2022 Universal Registration Document
Availability of Transgene’s 2022 Universal Registration Document 15
Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
Transgene to host KOL webinar on TG4050 15
Transgene Announces Upcoming Investor Meetings
Transgene announces upcoming investor meetings 15
Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
2022 full-year results and business update 15
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Transgene appoints John C Bell and Pedro Romero as Key Scientific advisors 15